Imperial College London
Professor Pallav Shah

ProfessorPallavShah

Faculty of Medicine, National Heart & Lung Institute

Professor of Respiratory Medicine
 
 
 
//

Contact

 

+44 (0)20 7351 8021pallav.shah

 
 
//

Location

 

Fulham RoadRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Horby:2021:10.1016/S0140-6736(21)00897-7,
author = {Horby, PW and Landray, MJ},
doi = {10.1016/S0140-6736(21)00897-7},
journal = {The Lancet},
pages = {2049--2059},
title = {Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial},
url = {http://dx.doi.org/10.1016/S0140-6736(21)00897-7},
volume = {397},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundMany patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.MethodsThis randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.FindingsBetween May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of pati
AU  - Horby,PW
AU  - Landray,MJ
DO  - 10.1016/S0140-6736(21)00897-7
EP  - 2059
PY  - 2021///
SN  - 0140-6736
SP  - 2049
TI  - Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(21)00897-7
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000656257800023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.sciencedirect.com/science/article/pii/S0140673621008977?via%3Dihubhttps://www.sciencedirect.com/science/article/pii/S0140673621008977?via%3Dihub
UR  - http://hdl.handle.net/10044/1/90411
VL  - 397
ER  -
Download